8-K filing — AETHLON MEDICAL INC (AEMD)
Filed: 2026-10-09 AccNo: 0001683168-26-007749 Size: 1 MB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Aethlon Medical, Oklo, CID HoldCo, Xenon Pharmaceuticals and Moderna: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average rising 0.61% to 51,778.04
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Shares of software companies are trading lower amid a broader technology sell-off led by declines in Micron and other semiconductor stocks. Comments from Intel and Broadcom CEOs that limited access to capital could constrain AI expansion, despite strong demand for computing infrastructure, are adding to concerns about the sustainability of tech-sector growth.
CID HoldCo shares are trading higher after the company announced it completed the acquisition of Envoy Technologies from BladeRanger in an all-stock transaction valued at ~$65 million.
CID Acquires Envoy Technologies From BladeRanger For ~$65M
CID HoldCo, Inc., doing business as Dot Ai (NASDAQ:DAIC) ("Dot Ai" or the "Company"), today announced that it has completed the acquisition of Envoy Technologies, Inc. ("Envoy") from BladeRanger
Nasdaq 100 Slides As Micron, SanDisk, CoreWeave Sink: Stock Market Today
The Nasdaq 100 fell 1.5% at midday Friday as memory chips and AI-debt names sold off, while Fed Chair Warsh declined to rule out an October hike after hot CPI and PPI. WTI held near $96, the 10-year yield hovered around 5.1%, gold bounced toward $4,200 and bitcoin traded near $81,300.
Meet the New Nasdaq-100 Stock That’s Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy?
Moderna stock has surged over 600% in 2026, outperforming major AI stocks like Nvidia, Micron, and Sandisk, driven by progress in its oncology pipeline, particularly its personalized cancer vaccine candidate intismeran autogene. The stock now trades 61% above Wall Street's average price target of $122, and while the company shows promise as it transforms from a coronavirus vaccine company into a broader biotech player, the analyst recommends waiting for a pullback before buying.